Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9796747 | 0.86 | TSHR (0.53) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL784062 | 0.83 | — | — | |
| SCHEMBL10988196 | 0.83 | HCAR2 (0.44) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL9752799 | 0.81 | TSHR (0.48) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL31037010 | 0.78 | TSHR (0.46) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL725912 | 0.78 | TSHR (0.60) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL2699105 | 0.77 | TSHR (0.59) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL662137 | 0.76 | THRB (0.50) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL838348 | 0.76 | TSHR (0.43) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL524105 | 0.74 | TSHR (0.42) | TSHRALDH1A1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115704053-A | Process method for manufacturing simulated sheepskin by coating two layers of sheepskins with organic silicon | 杭州希力高新材料科技有限公司 | 2023-02-17 | — | — | CN | claimed |
| US-5514749-A | SEALANTS | GENERAL ELECTRIC COMPANY (US) | 1996-05-07 | — | — | US | claimed |
| US-4129554-A | PICRIC ACID, QUINONE, CHLORANIL, CYANOACETATE ESTER | HITACHI CHEMICAL CO., LTD. (JP) | 1978-12-12 | — | — | US | claimed |
| CN-115704053-A | Process method for manufacturing simulated sheepskin by coating two layers of sheepskins with organic silicon | 杭州希力高新材料科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-10016405-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-30 | — | — | US | disclosed |
| US-20170056388-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9546126-B2 | Natural based branched compositions | AFI LICENSING LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9527882-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9469646-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9371331-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| WO-2012083970-A1 | REPELLENT COATING COMPOSITION AND COATING, METHOD FOR MAKING AND USES THEREOF | TEKNOLOGISK INSTITUT (DK) | 2012-06-28 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| EP-1206797-A1 | NANOPOROUS SILICA TREATED WITH SILOXANE POLYMERS FOR ULSI APPLICATIONS | AlliedSignal Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6318124-B1 | Nanoporous silica treated with siloxane polymers for ULSI applications | ALLIEDSIGNAL INC. | 2001-11-20 | — | — | US | disclosed |
| US-6284860-B1 | REACTING ORGANOPOLYSILOXANE(S) BEARING TERMINAL HYDROXYL GROUPS WITH AN ALKOXYSILANE HAVING AT LEAST TWO ALKOXY GROUPS AND A RADICAL WHICH CONTAINS AT LEAST ONE SECONDARY OR TERTIARY AMINO GROUP; ACIDIC PHOSPHATE CATALYST | WACKER-CHEMIE GMBH (DE) | 2001-09-04 | — | — | US | disclosed |
| WO-2001015214-A1 | NANOPOROUS SILICA TREATED WITH SILOXANE POLYMERS FOR ULSI APPLICATIONS | ALLIEDSIGNAL INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| US-4227083-A | Apparatus for infrared laser spectroscopy of room temperature vulcanizable silicone compositions | GENERAL ELECTRIC COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4129554-A | PICRIC ACID, QUINONE, CHLORANIL, CYANOACETATE ESTER | HITACHI CHEMICAL CO., LTD. (JP) | 1978-12-12 | — | — | US | disclosed |
| US-4083816-A | Acetoxymethyl derivatives of polyunsaturated fatty triglycerides as primary plasticizers for polyvinylchloride | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016405-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | TET1, TET3, EHMT2 | TSHR 4426/4885ALDH1A1 1213/4885CHRM2 1696/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | TSHR 3724/4885ALDH1A1 4257/4885CHRM2 4853/4885 |
| US-20170056388-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | TSHR 4426/4885ALDH1A1 1213/4885CHRM2 1696/4885 |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | TSHR 4415/4885ALDH1A1 2104/4885CHRM2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.